Creative Planning’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-24,691
Closed -$84K 2200
2018
Q3
$84K Hold
24,691
﹤0.01% 1817
2018
Q2
$93K Sell
24,691
-4,348
-15% -$21.2K ﹤0.01% 1784
2018
Q1
$119K Buy
29,039
+1,500
+5% +$6.99K ﹤0.01% 1719
2017
Q4
$128K Sell
27,539
-9,000
-25% -$49.6K ﹤0.01% 1696
2017
Q3
$259K Sell
36,539
-200
-0.5% -$1.44K ﹤0.01% 1431
2017
Q2
$266K Hold
36,739
﹤0.01% 1360
2017
Q1
$226K Hold
36,739
﹤0.01% 1414
2016
Q4
$215K Sell
36,739
-50
-0.1% -$273 ﹤0.01% 1382
2016
Q3
$195K Buy
36,789
+6,000
+19% +$32.4K ﹤0.01% 1410
2016
Q2
$204K Sell
30,789
-5,550
-15% -$31K ﹤0.01% 1248
2016
Q1
$170K Buy
36,339
+5,690
+19% +$22.7K ﹤0.01% 1300
2015
Q4
$155K Buy
30,649
+18,618
+155% +$88.5K ﹤0.01% 1367
2015
Q3
$42K Sell
12,031
-940
-7% -$6.29K ﹤0.01% 2164
2015
Q2
$129K Buy
12,971
+500
+4% +$5.36K ﹤0.01% 957
2015
Q1
$159K Sell
12,471
-2,100
-14% -$27K ﹤0.01% 1315
2014
Q4
$206K Buy
14,571
+3,200
+28% +$49.6K ﹤0.01% 1124
2014
Q3
$156K Sell
11,371
-5,934
-34% -$90.8K ﹤0.01% 1207
2014
Q2
$266K Buy
17,305
+7,671
+80% +$109K ﹤0.01% 896
2014
Q1
$164K Sell
9,634
-3,000
-24% -$45.3K ﹤0.01% 1102
2013
Q4
$164K Sell
12,634
-1,700
-12% -$20.3K ﹤0.01% 951
2013
Q3
$145K Sell
14,334
-100
-0.7% -$890 ﹤0.01% 908
2013
Q2
$108K Buy
+14,434
New +$113K ﹤0.01% 942

Creative Planning's KERX Position: Q4 2018 in Review

Creative Planning sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 24,691 shares — an estimated $84K sold.

Creative Planning first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $266K in Q2 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Creative Planning reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Creative Planning sold 24,691 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $84K.
  • Creative Planning first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
  • Creative Planning's Keryx Biopharmaceuticals Inc position peaked at $266K in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Creative Planning's 13F filing for Q4 2018, filed 1 Feb 2019.